TME Pharma N.V. (EPA:ALTME)

Market Cap	10.31M +6.8%
Revenue (ttm)	n/a
Net Income	-3.29M
EPS	-0.03
Shares Out	94.09M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,111,581
Open	0.1024
Previous Close	0.1074
Day's Range	0.0972 - 0.1096
52-Week Range	0.0490 - 0.1746
Beta	0.76
Analysts	n/a
Price Target	n/a
Earnings Date	May 7, 2026

About TME Pharma

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company’s Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is mid-stage clinical development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2 clinical trial for...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1997
• Employees: 12
• Stock Exchange: Euronext Paris
• Ticker Symbol: ALTME

Financial Performance

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 11, 2026

Data Sources Report a data error